- Conditions
- Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Interventions
- rimegepant 75 mg ODT, Matching placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 33
- States / cities
- La Mesa, California • Panorama City, California • Roseville, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 68
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Rhinosinusitis, Nasal Polyps
- Interventions
- Xolair placebo, Xolair (omalizumab)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Interventions
- OCEAN, Steroid-eluting sinus stent
- Device
- Lead sponsor
- Polyganics BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Colorado Springs, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Roseville, California • Upland, California + 21 more
- Conditions
- Nasal Polyps
- Interventions
- GSK5784283, Placebo, Standard of Care
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Plano, Texas
- Conditions
- Chronic Rhinosinusitis, Nasal Polyps
- Interventions
- Triamcinolone-impregnated CMC foam, Propel Stent
- Drug · Device
- Lead sponsor
- Marina Boruk
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- fluticasone nasal spray, Budesonide head upright, Budesonide head forward
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Stratford, Connecticut
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
- Interventions
- Dupilumab - Standard Dose
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina • Charlottesville, Virginia
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
- Conditions
- Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Interventions
- Not listed
- Lead sponsor
- The European Forum for Research and Education in Allergy and Airway Diseases
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Nasal Polyps
- Interventions
- Depemokimab (GSK3511294), Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
- Conditions
- Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
- Interventions
- gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
- Drug
- Lead sponsor
- LifeBridge Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Rhinosinusitis
- Interventions
- OPN-375
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Folsom, California • La Mesa, California + 16 more
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
- Interventions
- Benralizumab, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Sinusitis, Nasal Polyps
- Interventions
- S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray
- Drug · Procedure
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 19
- States / cities
- Atherton, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Chronic Rhinosinusitis
- Interventions
- OPN-375
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
- Biological · Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
- Conditions
- Chronic Sinusitis, Rhinosinusitis, Nasal Polyps
- Interventions
- Prednisone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Sinusitis, Nasal Polyposis
- Interventions
- S8 Sinus Implant, Mometasone furoate nasal spray, Sham
- Drug · Procedure
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Irvine, California • Sacramento, California + 33 more
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Interventions
- PF-06817024, Placebo for PF-06817024
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
- Conditions
- Nasal Polyps, Chronic Rhinosinusitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Roseville, California • Miami, Florida + 8 more